Geriatric assessment to improve recovery after CAR-T therapy for older patients with blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of geriatric assessment (GA) guided interventions aimed at enhancing functional recovery in patients aged 60 and older undergoing CAR-T therapy for B-cell non-Hodgkin lymphoma or multiple myeloma. Participants will be randomized into two groups: one receiving standard care and the other receiving GA-informed interventions, which include physical therapy and cognitive support. The study will assess various outcomes, including physical function, cognitive impairment, and quality of life at multiple time points post-treatment. The goal is to identify and mitigate potential side effects of CAR-T therapy in older adults through tailored interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ability to provide informed consent
* Patient's physician must agree for patient participation. A physician may elect to provide blanket agreement for participation of any eligible CAR-T patient under their care
* Ability to read English, or Spanish. Other languages will be acceptable with site principal investigator (PI) agreement if surveys are available and language does not preclude completing study procedures
* Age: \>= 60 years at the time of enrollment
* Scheduled to receive an Food and Drug Administration (FDA)-approved CAR-T for treatment of multiple myeloma or B-cell non- Hodgkin lymphoma
* Willing and able to complete study requirements
* Patients expect to be able to participate at least once before lymphodepletion with trimodality optimization visits

Exclusion Criteria:

* Prior CAR-T therapy
* Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Where it's running

• City of Hope Medical Center
  Duarte, California, United States Recruiting
• City of Hope at Irvine Lennar
  Irvine, California, United States Recruiting
• Wake Forest University, School of Medicine Dept. of Internal Medicine, Division of Hematology Oncology
  Winston-Salem, North Carolina, United States Recruiting
• Ohio State University Medical Center Dept. of Internal Medicine, Division of Hematology
  Columbus, Ohio, United States Recruiting

Study contacts

• Principal investigator: Andrew S Artz — City of Hope Medical Center

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In vivo CAR-T therapy for relapsed or refractory B‑cell leukemias, lymphomas, and multiple myeloma

  This trial will try a single in‑body (intravenous) CAR‑T infusion to treat adults with relapsed or refractory B‑cell acute lymphoblastic leukemia, B‑cell non‑Hodgkin lymphoma, or multiple myeloma.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT07239323

• BCMA-TGFβ CAR-T Cells in Relapsed or Refractory Myeloma

  A one-arm phase 1 study tests a new BCMA-TGFβ CAR-T cell therapy to see if it is safe and provides signs of benefit in adults whose multiple myeloma has come back or persisted after prior treatments.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05976555

• CAR-T therapy outcomes and quality of life in older adults with B‑cell lymphoma

  This project will see how CAR‑T therapy affects older adults (age 60+) with relapsed or refractory B‑cell lymphomas, focusing on daily function and quality of life while they receive standard care.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York · NCT04300998

• CAR-T Therapy Safety, Response, and Immune-Escape: Observational Study in Adults

  This observational study looks at adults who receive CAR-T cell therapy or bispecific antibodies to see which factors predict response and immune-related side effects.

  Recruiting IRCCS San Raffaele · Milan, Italy · NCT07915102

• Natalizumab to help prevent brain-related side effects during CAR-T therapy in certain lymphoma patients

  This phase 2 study tests whether natalizumab can reduce severe ICANS in adults with recurrent or refractory DLBCL or MCL receiving CAR-T therapy.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07892027

• CD19 CAR-T Therapy for Kids with Refractory Childhood SLE

  This study tests whether a patient’s own CD19 CAR-T cells can help children and young adults with severe, hard-to-treat lupus.

  Recruiting Phase 1 Seoul National University Hospital · Seoul · NCT07855302

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.